Lead exposure effect on angiotensin II renal vasoconstriction

Human and Experimental Toxicology

Volumn 26, Issue 6, 2007, Pages 499-507

  Robles, Hilda Vargas ^a   Romo, Eunice ^a   Sanchez Mendoza, Alicia ^b   Rios, Amelia ^a   Soto, Virgilia ^b   Avila Casado, M Carmen ^b   Medina, Armando ^b   Escalante, Bruno ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; ANGIOTENSIN II; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROETHIDINE; LEAD; LEAD ACETATE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRITE; SUPEROXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; HYPERTENSION; LEAD POISONING; MALE; MICROVASCULATURE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; VASOCONSTRICTION;

ADMINISTRATION, ORAL; ANGIOTENSIN II; ANIMALS; BLOTTING, WESTERN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; IMMUNOHISTOCHEMISTRY; INJECTIONS; KIDNEY; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; ORGANOMETALLIC COMPOUNDS; PAPAVERINE; PERFUSION; RATS; RATS, WISTAR; RENAL ARTERY; SUPEROXIDES; TYROSINE; VASOCONSTRICTION;

RATTUS NORVEGICUS;

EID: 34547650778     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1177/0960327106077597     Document Type: Article

References (32)

1. Victery W. Evidence for effects of chronic lead exposure on blood pressure in experimental animals: an overview. Environmental Health Perspectives 1988; 78: 71-76.
2. Khalil-Manesh F, Gonick HC, Weiler EW, Prins B, Weber MA, Purdy RE. Lead-induced hypertension: possible role of endothelial factors. American Journal of Hypertension 1993; 6: 723-29.
3. Ding Y, Vaziri ND, Gonick HC. Lead-Induced hypertension II. Response to sequential infusions of L-arginine, superoxide dismutase and nitroprusside. Environmental Research 1998; 76: 107-13.
4. Stephen JK, Barron JT, Tow JP. Cardiovascular action of lead and relationship to hypertension: A review. Environmental Health Perspectives 1988; 78: 91-99.
5. Skoczynska A, Wrobel J, Andrzejak R. Lead-cadmium interaction effect on the responsiveness of rat mesenteric vessels to norepinephrine and angiotensin II. Toxicology 2001; 162: 157-70.
6. Purdy RE, Smith JR, Ding Y, Oreisi F, Vaziri ND, Gonick HC. Lead-induced hypertension is not associated with altered vascular reactivity in vitro. American Journal of Hypertension 1997; 10: 997-1003.
7. Vaziri ND, Liang K, Ding Y. Increased nitric oxide inactivation by reactive oxygen species in lead-induced hypertension. Kidney International 1999a; 56: 1492-98.
8. Mugge A, Elwell JH, Peterson TE, Harrison DG. Release of intact endothelium-derived relaxing factor depends on endothelial superoxide dismutase activity. American Journal of Physiology 1991; 260: C219-25.
9. Farmand F, Ehdaie A, Roberts CHK, Sindhu RK. Lead-induced dysregulation of superoxide dismutases, catalase, glutathione peroxidase, and guanylate cyclase. Environmental Research 2005; 98: 33-39.
10. Sharifi AM, Darobi R, Akbarloo N, Larijani B, Khoshbaten A. Investigation of circulatory and tissue ACE activity during development of lead-induced hypertension. Toxicology Letters 2004; 153: 233-38.
11. Victery W, Thomas D, Schoeps P, Vander AJ. Lead increases urinary zinc excretion. Biological Trace Element Research 1982; 4: 211-19.
12. Meredith PA, Campbell CB, Blwer FH, Derkx M, Reid JL. The effects of lead on the rennin-angiotensin system. Xenobiotica 1985; 15: 521-28.
13. Peach MJ. Renin-angiotensin system: biochemistry and mechanisms of action. Physiological Reviewes 1977; 57: 313-70.
14. Lever AF, Lyall F, Morton JJ, Fulkon B. Angiotensin II vascular structure and blood pressure. Kidney International 1992; 41 (Suppl 3): S51-S55.
15. Martinez Y, Martinez S, Meaney A, Meaney E, Escalante B. Angiotensin II type I receptor blockade restores nitric oxide-dependent renal vascular responses in renovascular hypertension. Journal of Cardiovascular Pharmacology 2002; 40: 381-87.
16. Sanchez-Mendoza A, Hong E, Escalante B. The role of nitric oxide in angiotensin II-induced renal vasoconstriction in renovascular hipertension. Journal of Hypertension 1998; 16: 697-703.
17. 2 receptor expresión alter renal ablation. American Journal of Physiology. Renal Physiology 2005; 288: 207-13.
18. Luque D, Jimenez I, Martinez D, Segura B, Guadarrama JC, Paniaga R, Vargas H, Rios A, Escalante B. Hindlimb claudication reflects impaired nitric oxide-dependent revascularization alter ischemia. Vascular Pharma-cology 2007 Jan; 46(1): 10-15.
19. Courtois E, Marquez M, Barrientos A, Casado S, López-Farre A. Lead-induced downregulation of soluble guanylate cyclase in isolated rat aortic segments mediated by reactive oxygen species and cyclooxygenase-2. Journal of the American Society of Nrphrology 2003; 14: 1464-70.
20. Chai S, Webb RC. Effects of lead on vascular reactivity. Environmental Health Perspectives 1988; 78: 85-89.
21. Sigmon DH, Beierwaltes WH. Renal nitric oxide and angiotensin II interaction in renovascular hypertension. Hypertension 1993; 22: 237-42.
22. Luscher TF, Raij L, Vanhoutte PM. Endothelium-dependent responses in normotensive and hypertensive rats. Hypertension 1987; 8(Suppl II): 1161-66.
23. Mecca TE, Webb RC. Vascular responses to serotonin in steroid hypertensive rats. Hypertension 1984; 6: 887-92.
24. Tomera JF, Harakal C. Mercury- and lead-induced contraction of aortic smooth muscle in vitro. Archives International de Pharmacodoynamie et de Therapie 1986; 283: 295-302.
25. Zhang LF, Peng SQ, Wang S. Influence of lead (Pb2+) on the reactions of in vitro cultured rat aorta to 5-hydroxytryptamine. Toxicology Letters 2005; 159: 71-82.
26. Gonick HC, Ding y, Bondy SC, Ni Z, Vaziri ND. Lead-induced hypertension interplay of nitric oxide and reactive oxygen species. Hypertension 1997; 30: 1487-92.
27. Vaziri ND, Ding Y, Ni Z, Gonick HC. Altered nitric oxide metabolism and increased oxygen free radical activity in lead-induced hypertension: Effect of lazaroid therapy. Kidney International 1997; 52: 1042-46.
28. Vaziri ND, Ding Y, Ni Z. Nitric oxide synthase expresión in the course of lead-induced hipertension. Hypertension 1999b; 34: 558-62.
29. Vaziri ND, Ding Y, Ni Z. Compensatory up-regulation of nitric-oxide synthase isoforms in lead-induced hipertension; reversal by a superoxide dismutase-mimetic drug. Journal Pharmacology and Experimental Therapeutics 2001; 298: 679-85.
30. Attri J, Dhawan V, Mahmood S, Pandhi P, Parwana HK, Nath R. Effect of vitamin C supplementation on oxidative DNA damage in an experimental model of lead-induced hypertension. Annals of Nutrition & Metabolism 2003; 47: 294-301.
31. Khalil-Manesh F, Gonick HC, Weiler EWJ, Prins B, Weber MA, Purdy R, Ren Q. Effect of chelation treatment with dimercaptosuccinic acid (DMSA) on lead-related blood pressure changes. Environmental Research 1994; 65: 8.
32. Villa LM, Salas E, Darley-usmar VM, radomski MW, Moncada S. peroxynitrite induces both vasodilation and impaired vascular relaxation in the isolated perfused heratproc. Procedings National Academy of Science 1994; 91: 12383-87.